These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 19728887

  • 1. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.
    BMC Cancer; 2009 Sep 03; 9():311. PubMed ID: 19728887
    [Abstract] [Full Text] [Related]

  • 2. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
    Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K.
    Med Oncol; 2012 Sep 03; 29(3):2291-9. PubMed ID: 22081263
    [Abstract] [Full Text] [Related]

  • 3. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
    Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T.
    BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982
    [Abstract] [Full Text] [Related]

  • 4. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep 25; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 5. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.
    J Manag Care Pharm; 2008 Sep 25; 14(9):858-69. PubMed ID: 19006442
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL.
    Pirker R, Hedenus M, Vansteenkiste J, Hernandez E, Belton L, Terwey JH.
    Clin Ther; 2016 Jan 01; 38(1):122-135.e6. PubMed ID: 26730453
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
    Singh AK, Cizman B, Carroll K, McMurray JJV, Perkovic V, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Stankus N, Strutz F, Blackorby A, Cobitz AR, Meadowcroft AM, Paul G, Ranganathan P, Sedani S, Solomon S.
    JAMA Intern Med; 2022 Jun 01; 182(6):592-602. PubMed ID: 35377393
    [Abstract] [Full Text] [Related]

  • 8. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 01; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 9. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
    Warady BA, Barcia J, Benador N, Jankauskiene A, Olson K, Podracka L, Shavkin A, Srivaths P, Wong CJ, Petersen J.
    Pediatr Nephrol; 2018 Jan 01; 33(1):125-137. PubMed ID: 28815341
    [Abstract] [Full Text] [Related]

  • 10. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.
    Oncologist; 2007 Oct 01; 12(10):1253-63. PubMed ID: 17962619
    [Abstract] [Full Text] [Related]

  • 11. Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.
    Krause MW, Raja R, Agarwal A, Silver MR, Scarlata D, Sciarra A, Kewalramani R.
    Drugs Aging; 2009 Oct 01; 26(8):665-75. PubMed ID: 19685932
    [Abstract] [Full Text] [Related]

  • 12. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group.
    Clin Nephrol; 2005 Aug 01; 64(2):113-23. PubMed ID: 16114787
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
    Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, Endo Y, Hara K, Cobitz AR.
    Clin J Am Soc Nephrol; 2020 Aug 07; 15(8):1155-1165. PubMed ID: 32723804
    [Abstract] [Full Text] [Related]

  • 14. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P.
    Eur Heart J; 2007 Sep 07; 28(18):2208-16. PubMed ID: 17681958
    [Abstract] [Full Text] [Related]

  • 15. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.
    Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, Dreiling L.
    Br J Haematol; 2008 Jul 07; 142(3):379-93. PubMed ID: 18540943
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia.
    Boccia RV, Henry DH, Belton L, Bohac C, Ghazal HH.
    Cancer Med; 2016 Dec 07; 5(12):3445-3453. PubMed ID: 27882724
    [Abstract] [Full Text] [Related]

  • 17. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P.
    Am J Kidney Dis; 2013 Feb 07; 61(2):238-46. PubMed ID: 23159232
    [Abstract] [Full Text] [Related]

  • 18. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
    Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T, Miller C.
    Oncologist; 2008 Jun 07; 13(6):715-24. PubMed ID: 18586927
    [Abstract] [Full Text] [Related]

  • 19. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.
    Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, Locatelli F, Dougherty FC, Beyer U, ARCTOS Study Investigators.
    Clin J Am Soc Nephrol; 2008 Mar 07; 3(2):337-47. PubMed ID: 18287255
    [Abstract] [Full Text] [Related]

  • 20. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
    Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.
    Support Care Cancer; 2012 Jan 07; 20(1):159-65. PubMed ID: 21359879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.